Aerocrine Inc. Company Profile
Aerocrine AB is a medical technology company focused on the improved management and care of patients with inflammatory airway diseases. As the pioneer and leader in technology to monitor and manage airway inflammation, Aerocrine markets NIOX MINO® and NIOX Flex®. Both products enable fast and reliable management of airway inflammation and may therefore play a critical role in more effective diagnosis, treatment and follow-up of patients with inflammatory airway diseases such as asthma. Aerocrine is based in Sweden with subsidiaries in the U.S., Germany and the U.K. Aerocrine shares were listed on the Stockholm Stock Exchange in 2007.
News Articles
Change in Number of Shares and Votes in Aerocrine
Regulatory News: Aerocrine: (STO:AERO.B) With reference to Chapter 4 Section 9 in ”lagen (1991:980) om handel med finansiella instrument” it’s hereb...
Aerocrine raises $50 million in debt, equity
Aerocrine AB (SSE:AERO) raised about $50 million through a $35 million senior secured loan from OrbiMed and Novo A/S and a private placement to OrbiMed and institutional investors. In the placement, A...
Pharma deals debt financing of $50 million for Aerocrine
Aerocrine pharma deals for debt financing of $50 million which will be used for business development. The medical device company also raised financing of approx. USD 15 million of equity from OrbiMed...
Aerocrine completes $50M debt and equity financing
Aerocrine, a medical products company, has completed a financing with an affiliate of the U.S. investment firm OrbiMed Advisors and with Novo consisting of $35 million of debt. Aerocrine also raised $...
Aerocrine enters into a license agreement with Medisoft
Regulatory News: Aerocrine AB (STO:AERO-B) today announced the signing of a license agreement with Medisoft S.A. The agreement includes the withdrawal of all paten...
[Aerocrine] gets $49.1mm through private sale of debt/equity
Respiratory device firm [Aerocrine AB] has concurrently raised $35mm through the sale of debt to an OrbiMed Advisors affiliate and Novo, and another $14.1mm through a directed issue of 8.6mm shares at...
Aerocrine Passes Regulatory Milestone in Japan
Aerocrine AB (STO:AERO-B) announces that the Japanese authority (PMDA) has approved its FeNO (fractional exhaled nitric oxide)-measuring device, NIOX MINO ® from 2008 as a tool f...
Aerocrine Celebrates Grand Opening of US Headquarters in North Carolina’s Research Triangle
Aerocrine AB (OMX Nordic Exchange: AERO), a medical technology company focused on the improved management and care of patients with inflammatory airway diseases , today ann...
Drugs and Medications
None
PubMed Articles
Background and objective. Measuring the fraction of nitric oxide in exhaled breath (FE(NO)) is increasingly utilized to assess airway inflammation in asthma. The primary aim of this study was to compa...
Usefulness of Exhaled Nitric Oxide for Diagnosing Asthma.
Rationale. A standard asthma diagnosis is made based on clinical history, reversibility of airway obstruction, and bronchial hyperresponsiveness. Fractional exhaled nitric oxide (FeNO) is a noninvasiv...
Objective. Fractional exhaled nitric oxide (FeNO) is a non-invasive biomarker of airway inflammation. Our aim was to analyze the interrelationship and differentiate the predicting effects of asthma, a...
Background. Fractional exhaled nitric oxide (FeNO) measurement is a reliable, noninvasive marker of airway inflammation. The use of portable FeNO analyzers may enable the assessment of airway inflamma...
Clinical Trials
The purpose of this study is to demonstrate substantial equivalence between two medical devices which measure nitric oxide in exhaled breath, NIOX MINO® and NIOX® in Symptomatic Asthmati...
Measuring Exhaled Nitric Oxide (eNO) Using the Apieron INSIGHT System and the Aerocrine NIOX System
Collection of quantitative data to demonstrate the accuracy (bias) and precision (repeatability) of the Apieron INSIGHT(tm) eNO Breath System as compared to the FDA cleared NIOX eNO Breath...
Synopsis: LUNOKID-Study Investigation of Lung function Normal Values in Children and Adolescent in Germany For the diagnostic work-up of childhood airway diseases lungfunction measuremen...
Companies
Aerocrine AB is a medical technology company focused on the improved management and care of patients with inflammatory airway diseases. The pioneer and leader in the technology to...
Aerocrine AB is a medical technology company focused on the improved management and care of patients with inflammatory airway diseases. As the pioneer and leader in technology to...
Aerocrine AB is a medical technology company focused on the improved management and care of patients with inflammatory airway diseases. As the pioneer and leader in the technology...
Aerocrine is a clinically based medical, technical company with headquarters in Stockholm, Sweden. It was founded in 1997 by scientists at the Karolinska Institute that first identified Nitric Oxide (...
More Information about "Aerocrine Inc." on BioPortfolio
We have published hundreds of Aerocrine Inc. news stories on BioPortfolio along with dozens of Aerocrine Inc. Clinical Trials and PubMed Articles about Aerocrine Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Aerocrine Inc. Companies in our database. You can also find out about relevant Aerocrine Inc. Drugs and Medications on this site too.
